New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...